open access
Serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, and metabolic syndrome
, 2, 3, 3
Affiliations- Department of Internal Medicine, Faculty of Medicine, Firat University, Elazig, Türkiye
- Deparment of Family Medicine, Faculty of Medicine, Firat University, Elazig, Turkey
- Department of Biochemistry, Faculty of Medicine, Firat University, Elazig, Turkey
open access
Abstract
Introduction: The aim of this study was to investigate serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes and metabolic syndrome.
Material and methods: The study comprised 18 patients with type 2 diabetes mellitus (T2DM) (nine females, nine males), 18 patients with impaired fasting glucose (IFG) (nine females, nine males), 18 patients with impaired glucose tolerance (IGT) (nine females, nine males), 18 patients with metabolic syndrome (MeS) (nine females, nine males), and 16 healthy individuals (eight females, eight males); serum adiponectin, apelin, resistin levels, fasting and postprandial blood glucose, insulin resistance markers, and lipid parameters were measured.
Results: In the study, serum apelin levels were determined to be significantly lower in IGT, MeS, and T2DM groups compared with the control group (p = 0.002, p = 0.006, and p < 0.001, respectively). Serum resistin levels were determined to be significantly higher in IGT and T2DM groups compared with the control group (p < 0.001 and p < 0.001, respectively).
Conclusions: Apelin and resistin are thought to affect glucose metabolism and insulin resistance. Apelin is an important indicator in individuals with IGT in the prediabetic period and may play a role in preventing diabetic complications and treatment of T2DM.
Abstract
Introduction: The aim of this study was to investigate serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes and metabolic syndrome.
Material and methods: The study comprised 18 patients with type 2 diabetes mellitus (T2DM) (nine females, nine males), 18 patients with impaired fasting glucose (IFG) (nine females, nine males), 18 patients with impaired glucose tolerance (IGT) (nine females, nine males), 18 patients with metabolic syndrome (MeS) (nine females, nine males), and 16 healthy individuals (eight females, eight males); serum adiponectin, apelin, resistin levels, fasting and postprandial blood glucose, insulin resistance markers, and lipid parameters were measured.
Results: In the study, serum apelin levels were determined to be significantly lower in IGT, MeS, and T2DM groups compared with the control group (p = 0.002, p = 0.006, and p < 0.001, respectively). Serum resistin levels were determined to be significantly higher in IGT and T2DM groups compared with the control group (p < 0.001 and p < 0.001, respectively).
Conclusions: Apelin and resistin are thought to affect glucose metabolism and insulin resistance. Apelin is an important indicator in individuals with IGT in the prediabetic period and may play a role in preventing diabetic complications and treatment of T2DM.
Keywords
metabolic syndrome; pre-diabetes; apelin; resistin
About this articleTitle
Serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, and metabolic syndrome
Journal
Issue
Article type
Original paper
Pages
319-324
Published online
2020-05-15
Page views
1457
Article views/downloads
948
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2020;71(4):319-324.
Keywords
metabolic syndrome
pre-diabetes
apelin
resistin
Authors
Erhan Onalan
Burkay Yakar
Abdullah Onder Barım
Mehmet Ferit Gursu
References (19)- Onat T, Emerk K, Sözmen EY. İnsan Biyokimyası. Palme Yayıncılık, Ankara 2006: 280–285.
- Beck-Nielsen H. Clinical disorders of insulin resistance. In: Alberti K, DeFronzo RA, Keen H, Zimmet P. ed. International Textbook of Diabetes Mellitus. John Wiley&Sons, Chichester 1992.
- Simonson DC, Rossetti L, Giaccari A. Glucose toxicity. In: Alberti K, DeFronzo RA, Keen H, Zimmet P. ed. International Textbook of Diabetes Mellitus. John Wiley&Sons, Chichester 1992: 635–667.
- Yarımay Tevfikoğlu G. Tip 2 Diyabetli Bireylerin Çocuklarında Kan CRP, TNF Alfa, İnterlökin 6 ve Resistin Düzeylerinin İnsülin Direnci ile İlişkisi. Karaelmas Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Uzmanlık Tezi, Zonguldak 2010.
- Gürlek A. İnsülin direncinde genetik faktörler. In: Çorakçı A. ed. Klinik Endokrinoloji, Meta Basım, İzmir 2001: 49–53.
- Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 2002; 13(1): 18–23.
- Berger A. Resistin: a new hormone that links obesity with type 2 diabetes. BMJ. 2001; 322: 193.
- Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004; 50(9): 1511–1525.
- Heilbronn LK, Rood J, Janderova L, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab. 2004; 89(4): 1844–1848.
- Ort T, Arjona AA, MacDougall JR, et al. Recombinant human FIZZ3/resistin stimulates lipolysis in cultured human adipocytes, mouse adipose explants, and normal mice. Endocrinology. 2005; 146(5): 2200–2209.
- Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307–312.
- Hu H, He Lu, Li L, et al. Apelin/APJ system as a therapeutic target in diabetes and its complications. Mol Genet Metab. 2016; 119(1-2): 20–27.
- Akcılar R, Turgut S. Apelinin Kardiyovasküler Fonksiyonlar Üzerine Etkileri. Tıp Araştırmaları Dergisi. 2015; 13(3).
- Gourdy P, Cazals L, Thalamas C, et al. Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic‐euglycaemic clamp. Diabetes Obes Metab. 2017; 20(1): 157–164.
- Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005; 146(4): 1764–1771.
- Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005; 107(2): 198–211.
- Małyszko J, Małyszko JS, Koźminski P, et al. Apelin and cardiac function in hemodialyzed patients: possible relations? Am J Nephrol. 2006; 26(2): 121–126.
- Yue P, Jin H, Aillaud M, et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab. 2010; 298(1): E59–E67.
- Zhang Yu, Shen C, Li X, et al. Low plasma apelin in newly diagnosed type 2 diabetes in Chinese people. Diabetes Care. 2009; 32(12): e150.
